Oral Solid dosage (OSD) Contract Manufacturing Market to Grow with a CAGR of 6.52% through 2030
Increasing
regulatory compliance requirements pushing pharmaceutical firms to rely on
specialized contract manufacturers and rising demand for high-potency oral
solid dosage formulations, is expected to drive the Global Oral Solid dosage
(OSD) Contract Manufacturing Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “Oral Solid dosage (OSD) Contract Manufacturing
Market – Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2030F”, the Global Oral Solid dosage (OSD) Contract
Manufacturing Market stood at USD
40.92 Billion in 2024 and is expected to reach USD 59.86 Billion by
2030 with a CAGR of 6.52% during the forecast period. The
Global Oral Solid Dosage (OSD) Contract Manufacturing Market is expanding due
to rising demand for scalable and cost-efficient drug production solutions.
Pharmaceutical companies are increasingly partnering with contract development
and manufacturing organizations (CDMOs) to streamline operations, reduce
capital expenditures, and accelerate time-to-market. The growing burden of
infectious and chronic diseases, alongside an increasing focus on generic drug
production, is propelling the need for outsourced manufacturing services.
Regulatory requirements for drug quality and safety are prompting
pharmaceutical firms to rely on specialized CDMOs with expertise in compliance
and advanced production technologies. The surge in pharmaceutical product
approvals, particularly in oncology, neurology, and metabolic disorders, is
further driving demand for large-scale and flexible OSD manufacturing.
Continuous
advancements in drug formulation and production processes are reshaping the
market, leading to the emergence of novel drug delivery technologies and
improved patient adherence solutions. Enhanced formulation techniques, such as
multi-layer tablets and orally disintegrating tablets (ODTs), are gaining
traction due to their improved bioavailability and ease of administration.
Automation, artificial intelligence (AI), and digital process controls are
optimizing manufacturing efficiency, ensuring better quality control, and
reducing production errors. The adoption of high-potency active pharmaceutical
ingredients (HPAPIs) and controlled-release formulations is increasing,
requiring specialized containment and processing capabilities. Sustainability initiatives
are also gaining momentum, with contract manufacturers integrating green
chemistry practices, optimizing resource utilization, and implementing waste
reduction strategies to minimize environmental impact.
Significant
growth opportunities exist in emerging markets, where pharmaceutical demand is
rising due to expanding healthcare infrastructure and increasing medicine
accessibility. The shift toward personalized medicine is creating demand for
flexible, small-batch production capabilities, enabling CDMOs to cater to niche
therapeutic areas. The expanding pipeline of novel oral therapies, including
breakthrough drugs for rare diseases and biologics in tablet or capsule forms,
is driving investments in advanced formulation techniques. Increased
outsourcing from biotechnology startups and mid-sized pharmaceutical firms
looking to scale their production capabilities without heavy capital
investments presents a lucrative opportunity for contract manufacturers. Companies
that invest in automation, high-containment manufacturing, and regulatory
expertise will be well-positioned to capitalize on the evolving industry
dynamics.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Oral
Solid dosage (OSD) Contract Manufacturing Market”
The Global Oral
Solid dosage (OSD) Contract Manufacturing Market is segmented into product, end
user, regional distribution, and company.
Based on the Product,
Capsules emerged
as the fastest growing segment in the Global Oral Solid dosage (OSD) Contract
Manufacturing Market during the forecast period. This is due to their increasing preference among
pharmaceutical companies and consumers for enhanced drug delivery and patient
compliance. Capsules offer several advantages, including improved
bioavailability, better stability for sensitive drugs, and the ability to
encapsulate a wide range of formulations, including powders, granules, and
liquid-filled options. Their adaptability to both immediate-release and
controlled-release formulations has further driven their demand in contract
manufacturing. The growing demand for vegetarian and gelatin-based capsules has
played a significant role in the segment’s expansion, particularly among
health-conscious consumers and patients with dietary restrictions. The
pharmaceutical industry’s shift toward specialized and high-potency drug
formulations, such as oncology, nutraceuticals, and personalized medicine, has
also increased the adoption of capsules, as they provide an efficient vehicle
for complex drug delivery. Moreover, advancements in capsule-filling technologies,
including liquid-filled hard capsules (LFHC) and pellet encapsulation, have
made them an attractive choice for pharmaceutical companies seeking flexible
dosage forms with enhanced drug stability.
Based
on the Region, Asia-Pacific emerged as the fastest growing region in the Global
Oral Solid dosage (OSD) Contract Manufacturing Market during the forecast period. This is due
to its rapidly expanding pharmaceutical manufacturing sector, cost-effective
production capabilities, and increasing demand for generic and branded drugs.
The region has become a hub for contract manufacturing due to its lower labor
and operational costs, making it an attractive outsourcing destination for
global pharmaceutical companies. Countries like India, China, and South Korea
have heavily invested in expanding their pharmaceutical manufacturing
infrastructure, with government initiatives supporting local production and
export-driven growth. The rising prevalence of cardiovascular disorders,
diabetes, and infectious diseases has fueled the demand for cost-effective oral
solid dosage forms, particularly tablets and capsules. India’s well-established
generic drug industry, supported by a strong regulatory framework from agencies
like the U.S. FDA and EMA, has made it a preferred choice for outsourcing OSD
contract manufacturing. Meanwhile, China’s advanced pharmaceutical
manufacturing capabilities and increasing investments in research and
development (R&D) have further propelled the market's expansion.
Leading
contract manufacturing organizations (CMOs) in the region are adopting
automation, continuous manufacturing, and advanced formulation technologies to
enhance efficiency and meet global quality standards. The growing trend of
multinational pharmaceutical companies forming strategic partnerships with
Asia-Pacific CMOs to expand their production capabilities and market reach is
expected to further drive the region’s rapid growth in the OSD contract
manufacturing sector.
Major companies operating in Global Oral Solid dosage
(OSD) Contract Manufacturing Market are:
- AbbVie Inc.
- Acino International AG
- Aenova Holding GmbH
- Beximco Pharmaceuticals Ltd
- Boehringer Ingelheim International
GmbH
- Catalent Inc.
- Corden Pharma International GmbH,
- PerkinElmer Inc.
- Pyramid Laboratories Inc.
- Siegfried AG
Download
Free Sample Report
Customers can also request for 10%
free customization on this report
“The Global Oral
Solid Dosage (OSD) Contract Manufacturing Market is expanding due to the
increasing adoption of continuous manufacturing technologies, which enhance
production efficiency, reduce waste, and lower operational costs.
Pharmaceutical companies are shifting from traditional batch manufacturing to
continuous processes to meet growing demand, ensure consistent product quality,
and comply with evolving regulatory requirements. This shift is further
supported by regulatory agencies like the U.S. FDA, which actively promotes
advanced manufacturing techniques to improve drug supply chain resilience and
minimize environmental impact. The integration of real-time monitoring and
automation in OSD production is also driving higher precision and scalability,
making contract manufacturing an attractive option for pharmaceutical firms.,”
said Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Oral Solid dosage (OSD)
Contract Manufacturing Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, Segmented By Product (Tablets, Capsules, Powders,
Granules, Others), By End User (Large-size companies, Small & medium size
companies, Startups and generic pharmaceutical companies), By Region and
Competition, 2020-2030F”, has evaluated the future growth potential of Global
Oral Solid dosage (OSD) Contract Manufacturing Market and provides statistics
& information on market size, structure and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Oral Solid dosage (OSD) Contract Manufacturing Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York, United
States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com